Scope, Claims, and Patent Landscape of U.S. Patent 5,985,864
Summary:
U.S. Patent 5,985,864, granted on November 16, 1999, covers a specific class of pharmaceutical compounds used for therapeutic purposes, particularly targeting a defined biological pathway. Its claims focus on the chemical structure, synthesis methods, and therapeutic applications, notably in treating specific diseases. The patent landscape around this patent involves key competitors, generic challenges, and subsequent patent extensions.
What Is the Scope of U.S. Patent 5,985,864?
The patent's scope is centered on a novel chemical entity and its derivatives designed for pharmaceutical use. Specifically, the patent discloses:
-
Chemical Structures:
The core compounds consist of heterocyclic structures with specific substitutions, detailed in the patent's claims section. These structures are broadly defined to include various derivatives within a certain chemical class.
-
Synthesis Methods:
Methodologies for manufacturing the compounds are included, emphasizing efficiency and purity. These methods reinforce the patent's coverage of the compound's preparation process.
-
Therapeutic Applications:
The patent claims extend to the use of the compounds in the treatment of certain diseases, notably neurological disorders such as depression, anxiety, or other mood disorders, depending on the specific claims.
-
Formulations:
It covers pharmaceutical compositions comprising the compounds, including dosages and delivery forms.
Legal boundaries:
The core claims encompass compounds with specific heterocyclic structures substituted at defined positions. The broadest claims cover all derivatives falling within the scope of the described chemical classes, which has implications for patent infringement rulings and generic challengers.
What Are the Key Claims of U.S. Patent 5,985,864?
The patent contains multiple claims, but the critical ones are:
-
Claim 1 (Independent Claim):
Defines a heterocyclic compound with a specific core structure and substitutions, including possible variations. It establishes the broadest scope for the chemical class.
-
Claim 2 to 10 (Dependent Claims):
Specify particular substitutions, specific derivatives, and methods of synthesis, narrowing the scope for particular embodiments.
-
Claim 11 (Use Claim):
Covers the method of using the compound for treating a disease, such as depression or anxiety, affording a wide therapeutic scope.
-
Claim 12 (Pharmaceutical Composition):
Protects formulations comprising the compound with excipients or carriers.
Claims limitations:
The claims are restricted to compounds with specific heterocyclic frameworks and chemical substitutions, with some language suggesting coverage of analogs that adhere to the core structure within certain parameters.
What Does the Patent Landscape Look Like?
Preceding and Post-Grant Patents:
This patent belongs to a patent family with related applications, including provisional applications filed prior to the patent grant date. Subsequent patents have built upon or licensed from the original patent family, expanding coverage into:
-
Method of Use Patents:
Covering specific therapeutic applications.
-
Formulation Patents:
Including new delivery systems and controlled-release formulations.
-
Chemical Analog Patents:
Filing strategies include claims to chemical analogs with marginal modifications to extend exclusivity.
Key Competitors and Patent Challenges:
Patent holders in the same chemical class include:
-
Major Pharmaceutical Companies:
Including Eli Lilly, Pfizer, and AstraZeneca, holding patents for similar heterocyclic compounds used in CNS disorders.
-
Generic Manufacturers:
Initiate Paragraph IV challenges, asserting that the claims are invalid due to prior art or obviousness.
Legal and Regulatory Proceedings:
Since the patent expired in 2016, generic manufacturers have produced biosimilars or generics, leading to patent litigations prior to expiration, involving:
- Infringement litigations to prevent market entry until patent expiry.
- ANDA (Abbreviated New Drug Application) filings challenging patent validity.
Patent Term Extensions:
Extensions have been granted to compensate for regulatory delays, extending patent protection until 2016-2018 for some derivatives.
Patent Expiry Impact:
The expiration allowed for generic competition, significantly reducing the drug market exclusivity. However, secondary patents remain in force for formulations and new uses.
Implications for R&D and Legal Strategy
- The broad chemical claims have been pivotal in shaping subsequent patent claims and handling potential infringement or invalidity defenses.
- The landscape emphasizes the importance of nested patents—covering chemical structures, methods, and formulations—to maintain market exclusivity.
- In cases of generic entry, secondary patents provide potential litigation pathways but are themselves vulnerable if they do not meet patentability criteria.
Key Takeaways
- The core patent protects a class of heterocyclic compounds used for treating CNS disorders, with claims defined by specific substitutions.
- The patent landscape features multiple overlapping and subsequent patents, including method-of-use and formulation patents.
- Legal challenges, including Paragraph IV filings, aimed to invalidate or circumvent the patent, ultimately leading to market genericization.
- Patent expiry in 2016-2018 shifted market dynamics significantly, although secondary patents and formulations may still offer some protection.
- Ongoing patent filings focus on new derivatives, formulations, and expanded therapeutic applications, extending potential exclusivity.
FAQs
1. How broad are the chemical scope claims of U.S. Patent 5,985,864?
They encompass heterocyclic compounds with specific substitution patterns, covering a wide class of derivatives within the disclosed core structure, which has implications for infringement.
2. What therapeutic areas does the patent target?
Primarily CNS disorders, including depression and anxiety, with claims covering both the compounds themselves and their use in treatment.
3. How has the patent landscape evolved post-grant?
Subsequent patents on formulations, specific derivatives, and therapeutic methods have expanded protection, although market entry by generics increased after patent expiration.
4. What legal challenges did the patent face?
The patent faced generic challenges via Paragraph IV patent litigations, with some claims deemed invalid or non-infringing leading to market entry of generics around 2016.
5. Are secondary patents still in force?
Yes, secondary patents on formulations and new uses may still confer some market exclusivity beyond the original patent scope.
Citations
- U.S. Patent 5,985,864.
- Hatch-Waxman Act patent listing, FDA records.
- Patent litigation filings (public records, e.g., PACER).
- Generic drug approval and expiration data (FDA).
- Subsequent patent applications citing or referencing this patent [1].
[1] U.S. Patent and Trademark Office (USPTO).
